Should You Buy Vaxart in April?
Some stock traders have short attention spans. Shares can have dramatic rises over the course of months, only to be forgotten at the first sign of trouble. This is especially true in the biotech world, where data from a clinical trial can be the difference between billions in revenue or auctioning off scraps of intellectual property.
Vaxart (NASDAQ: VXRT) has already experienced this boom-and-bust cycle in 2021. But I think the forgotten drugmaker could be pausing before grabbing Wall Street's attention once again. If Vaxart can prove investors wrong, the stock may be back near all-time highs by summer.
Image source: Getty Images.
Source Fool.com
